BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment
Piotr Swat | Lightrocket | Getty Images CNBC Cures is proudly underwritten by Alexion, AstraZeneca Rare Disease, whose support enables our journalism to elevate stories that advance research, innovation and patient care in rare diseases. BioMarin Pharmaceutical is making more waves on the M&A front. […]
Health
